losartan has been researched along with nitroglycerin in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Broten, TP; Chakravarty, PK; Gabel, RA; Greenlee, WJ; Kivlighn, SD; Naylor, EM; Patchett, AA; Schaffer, LW; Schorn, TW; Zingaro, GJ | 1 |
| Cox, BF; Kitzen, JM; Perrone, MH; Smits, GJ | 1 |
| Freeman, BA; Griendling, KK; Harrison, DG; Kurz, S; Münzel, T; Rajagopalan, S; Tarpey, M | 1 |
| Mineshita, S; Shimakura, K; Wang, LM; Xu, ZH; Yamamoto, T | 1 |
| Borthayre, AB; Harrison, DG; Hink, U; Kurz, S; Münzel, T; Nickenig, G | 1 |
| Covi, G; Lechi, A; Montagna, L; Paluani, F; Pancera, P; Presciuttini, B; Sansone, S | 1 |
| Baldassarre, S; Berkenboom, G; Fontaine, D; Fontaine, J; Preumont, N; Unger, P | 1 |
| Azevedo, ER; Forster, C; Milone, SD; Parker, JD | 1 |
| Fujimura, A; Harada, K; Kawaguchi, A; Ohmori, M; Sugimoto, K | 1 |
| Berk, BC; Fox, RJ; Frame, MD; Kim, D; Mohan, A; Yan, C | 1 |
| Aldershvile, J; Andersen, C; Boesgaard, S; Gruhn, N | 1 |
| Chen, Y; Tang, T; Wang, X; Zhang, J | 1 |
| Abete, P; Cacciatore, F; Corbi, G; Ferrara, N; Furgi, G; Leosco, D; Longobardi, G; Pescatore, R; Rengo, F | 1 |
| Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Iwamoto, Y; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J | 1 |
| Bahde, R; Bandi, S; Bhargava, KK; Gupta, S; Kapoor, S; Palestro, CJ | 1 |
| Bagrov, DV; Chemeris, NK; Durymanov, MO; Kedrov, AV; Klinov, DV; Rosenkranz, AA; Sobolev, AS; Yarutkin, AV | 1 |
| Bergler-Czop, B; Brzezińska-Wcisło, L; Drobek, HH; Miziołek, B; Pietrauszka, K; Porwolik, M | 1 |
2 review(s) available for losartan and nitroglycerin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
What is the Best Way to Treat Patients with Raynaud's Phenomenon and a Tendency towards Hypotension?
Topics: Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypotension; Losartan; Nifedipine; Nitroglycerin; Raynaud Disease; Sildenafil Citrate; Smoking Cessation; Stress, Psychological; Vasodilator Agents | 2020 |
5 trial(s) available for losartan and nitroglycerin
| Article | Year |
|---|---|
Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Baroreflex; Blood Pressure; Cross-Over Studies; Female; Heart Rate; Humans; Losartan; Male; Nitroglycerin; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Single-Blind Method; Tilt-Table Test; Vasodilation | 1999 |
The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin.
Topics: Administration, Cutaneous; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Hematocrit; Hemodynamics; Humans; Losartan; Male; Nitroglycerin; Plethysmography; Vasodilator Agents | 1999 |
Effect of angiotensin II on venodilator response to nitroglycerin.
Topics: Adult; Analysis of Variance; Angiotensin II; Anti-Arrhythmia Agents; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Humans; Infusions, Intravenous; Losartan; Male; Middle Aged; Nitroglycerin; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2001 |
Angiotensin II-receptor antagonist losartan does not prevent nitroglycerin tolerance in patients with coronary artery disease.
Topics: Administration, Cutaneous; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Tolerance; Electrocardiography; Female; Heart Rate; Humans; Losartan; Male; Middle Aged; Nitroglycerin; Vasodilator Agents | 2004 |
Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cell Movement; Endothelium, Vascular; Eplerenone; Female; Humans; Hypertension; Leukocytes; Losartan; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nifedipine; Nitroglycerin; rho-Associated Kinases; Spironolactone; Stem Cells; Vascular Endothelial Growth Factor A; Vasodilation | 2012 |
12 other study(ies) available for losartan and nitroglycerin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Bradykinin; Dogs; Enalapril; Female; Imidazoles; Injections, Intravenous; Losartan; Macaca mulatta; Male; Nitroglycerin; Pan troglodytes; Pyridines; Rats; Rats, Sprague-Dawley; Tetrazoles | 1995 |
Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation.
Topics: Adenosine; Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Heart Rate; Imidazoles; Injections, Intravenous; Losartan; Male; Nifedipine; Nitroglycerin; Rats; Rats, Sprague-Dawley; Tetrazoles; Vascular Resistance; Vasodilation | 1993 |
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.
Topics: Acetylcholine; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Arginine; Biphenyl Compounds; Calcimycin; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Hypertension; Imidazoles; In Vitro Techniques; Losartan; Male; Muscle Relaxation; Muscle Tonus; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; Nitric Oxide Synthase; Nitroglycerin; Norepinephrine; omega-N-Methylarginine; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Superoxides; Tetrazoles | 1996 |
Pulmonary edema induced by angiotensin I in rats.
Topics: Adrenergic alpha-Antagonists; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Epinephrine; Losartan; Nitroglycerin; Phentolamine; Pulmonary Edema; Rats; Rats, Wistar; Receptors, Angiotensin; Regression Analysis; Respiration; Vasodilator Agents | 1998 |
Evidence for a causal role of the renin-angiotensin system in nitrate tolerance.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Tolerance; Endothelium, Vascular; Female; Gene Expression; Losartan; Luminescent Measurements; Male; Multienzyme Complexes; NADH, NADPH Oxidoreductases; NADPH Oxidases; Nitrates; Nitric Oxide; Nitroglycerin; Peptidyl-Dipeptidase A; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; RNA, Messenger; Sulfonamides; Superoxides; Vasoconstriction; Vasodilation; Vasodilator Agents | 1999 |
Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Thoracic; Bradykinin; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolerance; Endothelium, Vascular; In Vitro Techniques; Losartan; Male; Nitrates; Nitric Oxide Synthase; Nitroglycerin; omega-N-Methylarginine; Ramipril; Rats; Rats, Wistar; Superoxides; Time Factors; Vasodilator Agents | 1999 |
Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arterioles; Drug Tolerance; Free Radical Scavengers; Losartan; Male; Metalloporphyrins; Nitrates; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Superoxide Dismutase; Vasodilation | 2002 |
Nitroglycerin tolerance: different mechanisms in vascular segments with or without intact endothelial function.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Drug Interactions; Drug Tolerance; Endothelium, Vascular; Losartan; Male; Nitroglycerin; Rats; Rats, Wistar; Superoxide Dismutase; Vasodilation; Vasodilator Agents | 2002 |
Effect of angiotensin II receptor antagonist and endothelin receptor antagonist on nitroglycerin tolerance in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Drug Tolerance; Endothelin Receptor Antagonists; Losartan; Male; Nitroglycerin; Rats; Rats, Wistar; Sulfonamides; Vasodilator Agents | 2001 |
Directly acting drugs prostacyclin or nitroglycerine and endothelin receptor blocker bosentan improve cell engraftment in rodent liver.
Topics: Animals; Bosentan; Cardiovascular Agents; Dipeptidyl Peptidase 4; Endothelin Receptor Antagonists; Epoprostenol; Hepatocytes; Lisinopril; Liver; Losartan; Nitroglycerin; Rats; Rats, Inbred F344; Sulfonamides | 2013 |
Application of vasoactive and matrix-modifying drugs can improve polyplex delivery to tumors upon intravenous administration.
Topics: Administration, Intravenous; Angiotensin II; Animals; Cell Line, Tumor; Collagen Type I; DNA; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Green Fluorescent Proteins; Losartan; Luciferases, Firefly; Melanoma, Experimental; Mice, Inbred C57BL; Mice, Inbred DBA; Nanoparticles; Nitroglycerin; Oligopeptides; Polyethylene Glycols; Polyethyleneimine; Receptor, Melanocortin, Type 1; Regional Blood Flow; Vasoconstrictor Agents; Vasodilator Agents | 2016 |